Gossamer Bio (NASDAQ:GOSS) is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics in the areas of immunology, inflammation, and oncology. With a focus on addressing unmet medical needs, Gossamer Bio is actively advancing a diverse portfolio of clinical and preclinical projects aimed at providing new treatment options for patients. The company's objectives are to leverage its scientific expertise and operational efficiency to bring novel therapies from the laboratory to the clinic as swiftly and safely as possible. Through strategic collaborations and a commitment to research excellence, Gossamer Bio strives to improve health outcomes and enhance the quality of life for people around the globe.